The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene geperpavec) to treat patients with the ultra-rare genetic blistering disease ...

or B-VEC), a topical gene therapy for treating wounds in patients with dystrophic epidermolysis bullosa (DEB) who have specific genetic mutations. The recommendation allows for administration in ...

So, there is a reasonable theory as to why K2 might reduce the risk of calcification of the blood vessels, which is highly (but not perfectly) associated with blockages in the arteries to the heart.

Metabolic syndrome (MetSyn) is a group of metabolic conditions that occur together and promote the development of type 2 diabetes and cardiovascular disease. These include abdominal obesity ...

Treatment may not be necessary unless they cause pain. These calcifications are common, particularly in the pelvis. They are not usually a cause for concern and are rarely painful. However ...